Photo of Toni Choueiri from X
Jun 6, 2024, 04:56
Zach Klaassen: Biomarker analyses in aRCC from Ph 3 CLEAR trial by Toni Choueiri
Zach Klaassen, Urology Oncologist at Georgia Cancer Center, shared a post on X:
“Biomarker analyses in aRCC from Ph 3 CLEAR trial at ASCO24 by Toni Choueiri:
- Len + Pembro arm:
– Continuous GEP sig score not associated with the best resp
– MYC sig score: -ve associated with the best resp
– ORR MYC-high vs -low: 66.3% vs 84.0% - Sun arm:
– GEP sig score assoc with the best resp (p = 0.010)
– ORR GEP-high vs -low: 46.9% vs 28.8%
– Angiogenesis-high vs -low: 52.1% vs 30.4% - ORR/PFS: with Len + Pembro vs Sun, regardless of deleterious mutation status of BAP1, VHL, PBRM1, SETD2, KDM5C.”
Source: Zach Klaassen/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21